Lyell Immunopharma to Participate in the Piper Sandler 38th Annual Healthcare Conference

November 23, 2026

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present at the Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026, in New York, NY, at 4:10 pm Eastern Time.

A live webcast and subsequent replay of the Piper presentation will be available in the Investors section of the Company's website at www.lyell.com.

About Lyell Immunopharma, Inc.

Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T cells with enhancements needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. LyFE has commercial launch capability and is expected to have the capacity to manufacture more than 3,000 CAR T-cell doses per year. To learn more, please visit www.lyell.com.

Contact:

Lyell Investor Relations
IR@lyell.com